Diprovocim-1
| Code | Size | Price |
|---|
| TAR-T37722-50mg | 50mg | £771.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Diprovocim-1 is an agonist of the toll-like receptor 1/2 heterodimer.1It induces TNF-α release in THP-1 cells (EC50= 110 pM), an effect that can be inhibited by anti-TLR1 or anti-TLR2 antibodies. Diprovocim-1 (10 mg/kg) increases the production of ovalbumin-specific IgG1 in wild-type, but notTLR2-/-, mice sensitized to ovalbumin.2It also enhances anti-PD-L1 antibody-induced activation of cytotoxic T lymphocytes, reduction of tumor growth, and increases in survival in a B16/F10 murine melanoma model.
CAS:
2170867-89-5
Formula:
C56H56N6O6
Molecular Weight:
909.1
Purity:
0.98
SMILES:
O=C(C1=CC=C(C=C1)C(N2C[C@@H](C(N[C@@H]3[C@](C4=CC=CC=C4)([H])C3)=O)[C@H](C(N[C@@H]5[C@](C6=CC=CC=C6)([H])C5)=O)C2)=O)N7C[C@@H](C(N[C@@H]8[C@](C9=CC=CC=C9)([H])C8)=O)[C@H](C(N[C@@H]%10[C@](C%11=CC=CC=C%11)([H])C%10)=O)C7
References
Morin, M.D., Wang, Y., Jones, B.T., et al.Diprovocims: A new and exceptionally potent class of toll-like receptor agonistsJ. Am. Chem. Soc.140(43)14440-14454(2018)
Wang, Y., Su, L., Morin, M.D., et al.Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in miceProc. Natl. Acad. Sci. U.S.A.115(37)E8698-E8706(2018)